# A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

> **NCT01572038** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1436 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01572038
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-01
- **Primary completion:** 2019-09-20
- **Final completion:** 2019-09-20
- **Target enrollment:** 1436 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572038, "A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01572038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*